Across TCGA pan-cancer cohorts, LINC00052 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC00052 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher LINC00052 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC00052 expression acts as an unfavorable survival marker.
ESCA and SARC are the cancer types where LINC00052 Mutation most reproducibly stratifies survival.